ELDN vs. BIIB

Last updated Apr 1, 2026

Compare and contrast key facts about Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB).

Performance

ELDN vs. BIIB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB). The values are adjusted to include any dividend payments, if applicable.

ELDN vs. BIIB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ELDN Eledon Pharmaceuticals Inc	103.97%	-63.35%	128.89%	-21.05%	-48.30%	-71.36%	47.51%	-63.75%	-60.59%	-53.87%
BIIB Biogen Inc.	4.17%	15.09%	-40.91%	-6.55%	15.42%	-2.02%	-17.48%	-1.39%	-5.54%	12.34%

Fundamentals

EPS ELDN : -$1.03 BIIB : $8.82
Total Revenue (TTM) ELDN : $0.00 BIIB : $9.81B
Gross Profit (TTM) ELDN : -$88.00K BIIB : $6.91B
EBITDA (TTM) ELDN : -$92.78M BIIB : $3.10B

Returns By Period

In the year-to-date period, ELDN achieves a 103.97% return, which is significantly higher than BIIB's 4.17% return. Over the past 10 years, ELDN has underperformed BIIB with an annualized return of -43.53%, while BIIB has yielded a comparatively higher -3.45% annualized return.

ELDN

• 1D: 13.65%
• 1M: 17.56%
• YTD: 103.97%
• 6M: 18.92%
• 1Y: -9.14%
• 3Y*: 9.28%
• 5Y*: -23.49%
• 10Y*: -43.53%

BIIB

• 1D: -2.26%
• 1M: -4.43%
• YTD: 4.17%
• 6M: 30.88%
• 1Y: 33.97%
• 3Y*: -12.96%
• 5Y*: -8.04%
• 10Y*: -3.45%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ELDN vs. BIIB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELDN

ELDN Risk / Return Rank: 40
ELDN Sharpe Ratio Rank: 36
ELDN Sortino Ratio Rank: 43
ELDN Omega Ratio Rank: 46
ELDN Calmar Ratio Rank: 37
ELDN Martin Ratio Rank: 38

BIIB

BIIB Risk / Return Rank: 73
BIIB Sharpe Ratio Rank: 75
BIIB Sortino Ratio Rank: 72
BIIB Omega Ratio Rank: 66
BIIB Calmar Ratio Rank: 77
BIIB Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ELDN vs. BIIB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ELDN	BIIB	Difference
Sharpe ratio Return per unit of total volatility	-0.10	0.99	-1.09
Sortino ratio Return per unit of downside risk	0.55	1.63	-1.09
Omega ratio Gain probability vs. loss probability	1.09	1.19	-0.10
Calmar ratio Return relative to maximum drawdown	-0.12	1.90	-2.01
Martin ratio Return relative to average drawdown	-0.22	4.80	-5.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ELDN vs. BIIB - Sharpe Ratio Comparison

The current ELDN Sharpe Ratio is -0.10, which is lower than the BIIB Sharpe Ratio of 0.99. The chart below compares the historical Sharpe Ratios of ELDN and BIIB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ELDN	BIIB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.10	0.99	-1.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.30	-0.21	-0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.39	-0.08	-0.31
Sharpe Ratio (All Time) Calculated using the full available price history	-0.44	0.22	-0.66

Correlation

The correlation between ELDN and BIIB is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ELDN vs. BIIB - Dividend Comparison

Neither ELDN nor BIIB has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ELDN vs. BIIB - Drawdown Comparison

The maximum ELDN drawdown since its inception was -99.97%, which is greater than BIIB's maximum drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for ELDN and BIIB.

Drawdown Indicators

	ELDN	BIIB	Difference
Max Drawdown Largest peak-to-trough decline	-99.97%	-89.98%	-9.99%
Max Drawdown (1Y) Largest decline over 1 year	-68.12%	-14.13%	-53.99%
Max Drawdown (5Y) Largest decline over 5 years	-90.47%	-72.66%	-17.81%
Max Drawdown (10Y) Largest decline over 10 years	-99.92%	-72.66%	-27.26%
Current Drawdown Current decline from peak	-99.92%	-61.48%	-38.44%
Average Drawdown Average peak-to-trough decline	-91.88%	-36.48%	-55.40%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.11%	6.78%	+30.33%

Volatility

ELDN vs. BIIB - Volatility Comparison

Eledon Pharmaceuticals Inc (ELDN) has a higher volatility of 23.12% compared to Biogen Inc. (BIIB) at 8.91%. This indicates that ELDN's price experiences larger fluctuations and is considered to be riskier than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ELDN	BIIB	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.12%	8.91%	+14.21%
Volatility (6M) Calculated over the trailing 6-month period	88.61%	24.16%	+64.45%
Volatility (1Y) Calculated over the trailing 1-year period	90.59%	34.48%	+56.11%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	78.72%	38.11%	+40.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	110.65%	41.40%	+69.25%

Financials